ストックスクリーナーアプリを入手
132.16
0.20%
-0.27
アフターアワーズ：
133.67
1.51
+1.14%
前日終値:
$132.43
開ける：
$133.82
24時間の取引高:
2.00M
Relative Volume:
1.25
時価総額：
$253.59B
収益：
$54.45B
当期純損益:
$14.42B
株価収益率:
18.02
EPS:
7.333
ネットキャッシュフロー:
$17.15B
1週間 パフォーマンス:
+1.35%
1か月 パフォーマンス:
+5.31%
6か月 パフォーマンス:
+12.20%
1年 パフォーマンス:
+28.91%
1日の値動き範囲:
$132.09
$134.04
1週間の範囲:
$128.91
$134.24
52週間の値動き範囲:
$96.06
$134.24
Novartis Ag Adr Stock (NVS) Company Profile
NVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
132.16 | 254.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
LLY
Lilly Eli Co
|
1,010.31 | 907.99B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.93 | 487.83B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.08 | 404.22B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
99.72 | 250.41B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-09-12 | ダウングレード | Goldman | Neutral → Sell |
| 2025-08-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | ダウングレード | UBS | Buy → Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Underweight |
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035 by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players - GlobeNewswire Inc.
TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz
Why Novartis Stock Topped the Market Today - sharewise.com
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth - Finviz
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Sahm
Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Finviz
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring - Sahm
Net margin % of Novartis AG Sponsored ADR – HAM:NOTA - TradingView
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz
Novartis Issues $6 Billion in Debt Securities to Bolster Financial Strategy - The Globe and Mail
Stocks Generating Improved Relative Strength: Novartis ADR - Investor's Business Daily
Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar
Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India
Novartis completes acquisition of Tourmaline Bio - Novartis
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm
Novartis announces expiration of Tourmaline Bio tender offer - Novartis
Stocks Rally on US-China Preliminary Trade Agreement - Barchart.com
Avidity Biosciences Soars After $72 Per Share Novartis Takeover - Sahm
Market movers: Qualcomm, Avidity Biosciences, Lululemon, Keurig Dr Pepper… - Proactive financial news
Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal - Sahm
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline - Novartis
Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock - Sahm
Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis
Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm
Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
1.16%
1.28%
大文字化:
|
ボリューム (24 時間):